Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Olendalizumab

Copy Product Info
😃Good
Catalog No. T77107Cas No. 2210314-30-8
Alias Lendalizumab, ALXN1007

Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).

Olendalizumab

Olendalizumab

Copy Product Info
😃Good
Catalog No. T77107Alias Lendalizumab, ALXN1007Cas No. 2210314-30-8
Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Olendalizumab (ALXN-1007) is a humanized monoclonal antibody specifically targeting the complement component C5a. The compound binds to C5a, blocking its interaction with the C5aR (CD88) receptor, thereby inhibiting C5a-mediated inflammatory responses, neutrophil chemotaxis, and activation. In clinical and experimental research, Olendalizumab is investigated for treating complement-mediated disorders, such as sepsis, graft-versus-host disease (GVHD), and severe pneumonia or cytokine storms induced by viral infections (e.g., COVID-19).
In vitro
In a Gyrolab assay, Olendalizumab demonstrated high specificity as a biotinylated capture reagent (working concentration: 100 µg/mL in Bioaffy wash 1), working alongside AlexaFluor-labeled anti-C5a clone 2942 (4 µg/mL in Rexxip F) to enable precise quantitation of free C5a in human plasma [1].
In vivo
In viral infection models, Olendalizumab acted as a potent C5a inhibitor to mitigate lung injury mediated by complement components (C3, C5a, C5b-9) and receptors (C3aR, C5aR), specifically blocking the non-silent complement activation triggered by coronaviruses [2].
SynonymsLendalizumab, ALXN1007
Reactivity
Virus
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetComplementproteinC5a
Chemical Properties
Cas No.2210314-30-8
Antibody Information
IsotypeIgG2SA
Storage & Solubility Information
Storagestore at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Olendalizumab | purchase Olendalizumab | Olendalizumab cost | order Olendalizumab | Olendalizumab in vivo | Olendalizumab in vitro